Novo Nordisk A/S (NVO) announced on Thursday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has endorsed an update to the labeling of their weight-loss medication, Ozempic, to include the potential for reducing the risk of kidney disease. This decision arises from the results of the FLOW trial, which evaluated the effects of Ozempic, a weekly administered subcutaneous semaglutide, on chronic kidney disease-related outcomes.
The trial, which was randomized, double-blind, and placebo-controlled, demonstrated that semaglutide at a dose of 1.0 mg lowered the risk of kidney disease by 24%. It also showed an 18% reduction in the risk of major cardiovascular events and a 20% decrease in all-cause mortality.
Novo Nordisk, headquartered in Denmark, has also pursued a similar label expansion in the United States, with an anticipated decision expected in the first half of 2025.
At present, the company's stock is trading at $110.57 on the New York Stock Exchange, reflecting a 1% decrease.
The material has been provided by InstaForex Company - www.instaforex.com
The trial, which was randomized, double-blind, and placebo-controlled, demonstrated that semaglutide at a dose of 1.0 mg lowered the risk of kidney disease by 24%. It also showed an 18% reduction in the risk of major cardiovascular events and a 20% decrease in all-cause mortality.
Novo Nordisk, headquartered in Denmark, has also pursued a similar label expansion in the United States, with an anticipated decision expected in the first half of 2025.
At present, the company's stock is trading at $110.57 on the New York Stock Exchange, reflecting a 1% decrease.
The material has been provided by InstaForex Company - www.instaforex.com